Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ:RXRX)

5.860 -0.500 (-7.86%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Recursion Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Our AI-Focused Drug Discovery Stocks Portfolio Down 8% In August; Down 6.7% Yesterday Alone!
The August ISM manufacturing index reported on Tuesday that figures came in below consensus expectation. That raised fears about the strength of the economy, driving down our Our AI-Focused Drug... 
Via Talk Markets
Topics Economy
Decoding 6 Analyst Evaluations For Recursion Pharmaceuticals
 
Via Benzinga
Crude Oil Dips Over 4%; SPAR Group Shares Spike Higher
 
Via Benzinga
Nasdaq Dips Over 2%; US Construction Spending Falls In July
 
Via Benzinga
Recursion Pharmaceuticals Stock Is Sliding Tuesday: What's Going On?
Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares are trading lower. The company on Tuesday announced Phase 2 data for an investigational treatment for symptomatic Cerebral Cavernous Malformation... 
Via Benzinga
How Is The Market Feeling About Recursion Pharmaceuticals?
 
Via Benzinga
Recursion updates L(earnings) call on August 8th to 8:30 am ET / 6:30 am MT
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion to Report Second Quarter 2024 Business Updates and Financial Results on August 8th
Company to host public L(earnings) call on August 8th at 5:00 pm ET / 3:00 pm MT 
From Recursion Pharmaceuticals
Via GlobeNewswire
Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
 
Via Benzinga
Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability
REC-994 also demonstrates encouraging trends in objective MRI-based exploratory efficacy measures at the highest dose and the company plans to advance development of REC-994 for the potential treatment... 
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
Is Recursion Pharmaceuticals a Warren Buffett Stock?
Don't expect Buffett to invest in this stock tomorrow, but it has the potential to eventually be a stock he would consider. 
Via The Motley Fool
Our AI-Focused Drug Discovery Stocks Portfolio Was Up Almost 7% Last Week
The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030. 
Via Talk Markets
The Bull Thesis for Recursion Pharmaceuticals Stock Just Got Stronger. Here's Why.
Merging with a former rival will bolster its capabilities. 
Via The Motley Fool
Is Recursion Pharmaceuticals Stock a Buy?
We'll know a little more about the biotech's prospects in a year and a half. 
Via The Motley Fool
AI-Focused Drug Discovery Stocks Portfolio Hit Hard: Down 14% MTD
The AI-powered drug discovery process is expected to grow by a 30% CAGR between now and 2030 which should result in approximately 50 novel therapies and generate annual sales in excess of $50 billion... 
Via Talk Markets
How A.I. Is Shaping the Future of U.S. Healthcare: Regulatory and Market Updates
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:EXAI),(NASDAQ:TWST),(NYSE:IQV) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
How A.I. Is Shaping the Future of U.S. Healthcare: Regulatory and Market Updates
From FN Media Group LLC
Via GlobeNewswire
Prediction: Artificial Intelligence Will Lead to Higher Returns With Biotech Stocks
Efficiency in core processes is set to increase substantially due to AI. 
Via The Motley Fool
Topics Artificial Intelligence
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RXRX, GVP, OBDE, OBDC on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
Prediction: Buying Biotech and Pharma Stocks During This Sell-Off Will Be a Smart Move
There isn't much to suggest these businesses are actually vulnerable. 
Via The Motley Fool
Is Recursion Pharmaceuticals a Buy Ahead of Its Merger With Exscientia?
The leading company pioneering artificial intelligence (AI)-fueled drug discovery could get much bigger. 
Via The Motley Fool
Topics Artificial Intelligence
AI-Powered Drug Discovery Firm Exscientia To Merge With Nvidia-Partner Recursion Pharmaceuticals
Exscientia merges with Recursion Pharmaceuticals in an all-stock deal. The new entity, named Recursion, will focus on industrializing drug discovery with advanced AI technologies, boasting $850 million... 
Via Benzinga
Topics Artificial Intelligence
RXRX Stock Earnings: Recursion Pharmaceuticals Meets EPS, Beats Revenue for Q2 2024
RXRX stock results show that Recursion Pharmaceuticals met analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
CORRECTION - Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results
From Recursion Pharmaceuticals
Via GlobeNewswire
RXRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Recursion Pharmaceuticals, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities
Operational complementarities expected to yield annual synergies of approximately $100 million 
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results
From Recursion Pharmaceuticals
Via GlobeNewswire
Is Recursion Pharmaceuticals a Millionaire-Maker?
It's likely to experience a lot of growth. 
Via The Motley Fool
99.9% of Nvidia's $380 Million Investment Portfolio Has Been Put to Work in These 4 Artificial Intelligence (AI)-Inspired Stocks
Artificial intelligence (AI) colossus Nvidia has stakes in five publicly traded companies -- four of which account for almost every cent of its AI-driven portfolio. 
Via The Motley Fool
Topics Artificial Intelligence
AI-Focused Drug Discovery Stocks Portfolio Up 7% Last Week; Up 19% MTD
The AI-powered drug discovery process is expected to grow by a CAGR of 30% by 2030. 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.